<unk><unk>  co-transporter<unk>  (SGLT2)<unk>  (dapagliflozin or empagliflozin) are recommended for patients with HFrEF regardless of the presence or absence of diabetes, in addition to optimal medical therapy with an ACE-I/ARNI, a beta-blocker, and an aldosterone antagonist.
Congestive heart failure Sodium-glucose co-transporter 2 inhibitors
Congestive heart failure angiotensin receptor-neprilysin inhibitor
Congestive heart failure aldosterone antagonists
Congestive heart failure calcium channel blockers
Congestive heart failure diuretics
Congestive heart failure vasodilators
Congestive heart failure electrolyte replacement
Congestive heart failure Treatment of Heart failure with preserved ejection fraction